Loading clinical trials...
Loading clinical trials...
Open-label, Multicentre, Tolerability, Safety and Pharmacokinetics Study of the Medicinal Product BP-SCIG 20% (Human Normal Immunoglobulin for Subcutaneous Administration) Manufactured by BIOPHARMA PLASMA LLC, Followed by an Efficacy Assessment of Long-term Use in Patients With Primary Immunodeficiency (PID)
Conditions
Interventions
BP-SCIG 20%
Locations
12
Ukraine
Municipal Non-Profit Enterprise "Cherkasy Regional Children's Hospital" of the Cherkasy Regional Council
Cherkasy, Ukraine
Regional Municipal Non-Profit Enterprise "Chernivtsi Regional Teaching Hospital"
Chernivtsi, Ukraine
Municipal Non-Profit Enterprise "Ivano-Frankivsk Regional Teaching Hospital" of the Ivano-Frankivsk Regional Council
Ivano-Frankivsk, Ukraine
Municipal Non-Profit Enterprise "Ivano-Frankivsk Regional Children's Teaching Hospital" of the Ivano-Frankivsk Regional Council
Ivano-Frankivsk, Ukraine
Municipal Non-Profit Enterprise "Kyiv City Children's Teaching Hospital No. 1"
Kyiv, Ukraine
LLC "Allergy and Cough Clinic"
Lutsk, Ukraine
Start Date
December 17, 2025
Primary Completion Date
April 17, 2028
Completion Date
July 1, 2028
Last Updated
January 16, 2026
NCT05236764
NCT05755035
NCT05513586
NCT06955793
NCT03277313
NCT01218438
Lead Sponsor
Biopharma Plasma LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions